Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Therapeutics Stands to Gain $300,000 in Stock-Purchase Warrant Placed With Lender

This article corrects an earlier version that reported that Lynx had sold $300,000 worth of shares to Silicon Valley Bank. In fact, the company issued a warrant for the bank to buy the stock.


NEW YORK, Jan. 25 (GenomeWeb News) - Lynx Therapeutics stands to gain $300,000 from a stock-purchase warrant issued to Silicon Valley Bank, according to a Jan. 3 SEC filing.


The warrant gives the bank the option to buy 95,541 shares at $3.14 a piece between Dec. 28, 2004, and Dec. 27, 2007. It is part of the bank's agreement earlier this month to give Lynx a $3 million bridge loan.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.